Sector: MedicalPharmaceutical Resources, Inc. (NYSE: PRX)
Ranking History
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 62 |
Technical : | 216 |
Performance : | 61 |
Overall: | 85 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 28 |
Technical : | 188 |
Performance : | 65 |
Overall: | 50 |
Number of Stocks: | 306 |
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 24 |
Technical : | 230 |
Performance : | 106 |
Overall: | 90 |
Number of Stocks: | 306 |
Headlines
- Par Pharmaceutical to Host Analyst Day on December 3rd
Nov 16, 2009 04:15 PM | PRX
- Par Pharmaceutical Receives Final Approval to Market Generic Ultram(R) ER
Nov 16, 2009 08:15 AM | JNJ, PRX, RX
- Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010
Nov 09, 2009 05:46 PM | PRX
- Par Pharmaceutical Reports EPS of $0.76 for Third Quarter 2009
Nov 06, 2009 07:30 AM | PRX
- Information You Can Use if You Have High Blood Pressure: TOPROL-XL(R) and its Generic Equivalent, Metoprolol Succinate
Oct 27, 2009 09:02 AM | AZN, PRX
- Caris Diagnostics Names Jerry Martino Senior Vice President, Chief Financial Officer
Oct 26, 2009 10:47 AM | PRX, SGP
- Joy Global (JOYG) Options Active At The Close
Oct 19, 2009 05:07 PM | CAT, IOC, JOYG, PRX, QLGC
- Par Pharmaceutical Announces 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010
Oct 14, 2009 05:10 PM | PRX
- Clinical Data, Inc. Announces Pharmaceutical Industry Leader Joins the Board of Directors
Sep 18, 2009 07:30 AM | CLDA, PRX
- Strativa Pharmaceuticals' Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
Sep 14, 2009 02:29 PM | PRX
- FDA Accepts Drug Application for Miconazole Lauriad(R) to Treat Oropharyngeal Candidiasis
Aug 19, 2009 08:01 AM | PRX
- Par Pharmaceutical & Aveva Drug Delivery Systems Receive Final Approval to Market Generic Catapres TTS(R)
Aug 18, 2009 06:38 PM | PRX
- Par Pharmaceutical Wins on Invalidity in Ultram(R) ER Litigation
Aug 17, 2009 08:02 AM | PRX
- StockPreacher.com issues Trading Outlook for Spectrum Pharmaceuticals Inc.
Aug 05, 2009 06:50 AM | AGN, BMY, JNJ, PRX, SPPI
- Par Pharmaceutical Reports EPS of $0.71 for Second Quarter 2009
Aug 04, 2009 07:51 AM | AZN, PRX
- Par Pharmaceutical to Host Second Quarter 2009 Earnings Conference Call on August 4 at 9:00 am
Jul 15, 2009 09:02 AM | PRX
- Protox to present benign prostatic hyperplasia data at Canadian Urology Conference
Jun 29, 2009 07:00 AM | PRX
- Strativa's Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA
Jun 16, 2009 09:26 AM | PRX
- Thomas P. Rice Elected to Board of Directors of Par Pharmaceutical Companies, Inc.
Jun 12, 2009 08:30 AM | PRX
- MonoSol Rx Announces FDA Acceptance of NDA for Ondansetron Orally Dissolving Film Strip
Jun 10, 2009 08:02 AM | PRX
- Form 4 LEPORE PATRICK G For: Oct 30 (10K)
Nov 02, 2009 05:58 PM
- Form 4 SHAROKY MELVIN MD For: Oct 05 (10K)
Oct 06, 2009 04:33 PM
- Form 4 SMITH JOSEPH E For: Oct 05 (10K)
Oct 06, 2009 04:25 PM
- Form 4 KNIGHT PETER S For: Oct 05 (10K)
Oct 06, 2009 04:03 PM
- Form 4 MacPhee John A For: Sep 09 (10K)
Sep 10, 2009 05:43 PM
- Form 4 HAUGHEY THOMAS For: Aug 25 (10K)
Aug 26, 2009 03:59 PM
- Form 4 Campanelli Paul For: Aug 24 (10K)
Aug 26, 2009 03:40 PM
- Form 4 DEERFIELD INTERNATIONAL For: Aug 17 (10K)
Aug 19, 2009 08:03 PM
- Form 4 LEPORE PATRICK G For: Aug 10 (10K)
Aug 12, 2009 12:12 PM
- Form 4 SHAROKY MELVIN MD For: Jul 01 (10K)
Jul 02, 2009 11:09 AM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
PRX
|
Compare to S&P
|
| YTD |
74.87 %
|
44.73 %
|
| 4 Weeks |
8.62 %
|
7.44 %
|
| 12 Weeks |
14.61 %
|
8.06 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 18.46 %
|
|
EPS Growth in Last Year: 196.15 %
|
|
Sales Growth in Last Quarter: -27.03 %
|
|
Sales Growth in Last Quarter: 97.90 %
|
|
